Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

134.07 +2.29 (+1.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Neurocrine Biosciences Inc (NASDAQ:NBIX) Qualifies for Affordable Growth Screen with Strong GARP Profile ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Combines Strong Fundamentals with a Bullish Technical Setup ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top Affordable Growth Stock ↗
Via Chartmill
News headline image
Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive... 
Via MarketMinute
News headline image
Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology
Date: April 7, 2026 Introduction Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has long been a bellwether for the mid-cap biotechnology sector, serving as a primary case study in how a company can... 
Via Finterra
Topics Earnings Economy Intellectual Property
Neurocrine Biosciences Inc. (NASDAQ:NBIX) Presents a Strong Growth and Technical Setup ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Case as a Quality Value Stock ↗
Via Chartmill
News headline image
Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
The following feature explores the trajectory of Soleno Therapeutics as of April 7, 2026. Introduction On the morning of April 7, 2026, the biotechnology sector is processing one of the most... 
Via Finterra
Topics Economy Intellectual Property
Wall Street Holds Its Ground While Trump's Iran Deadline Ticks Down ↗
Via Chartmill
Topics Government
News headline image
Why Soleno Therapeutics Stock Rocketed Higher on Monday ↗
It's being acquired by a peer. 
Via The Motley Fool
News headline image
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has... 
Via MarketMinute
Topics Intellectual Property
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top GARP Pick with Strong Growth and a Reasonable Price ↗
Via Chartmill
News headline image
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗
This clinical-stage biotech focuses on developing therapies for neurological and immunoscience disorders. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)
As of March 10, 2026, the biopharmaceutical sector is witnessing a historic realignment in the neurology space, spearheaded by the Canadian-born clinical powerhouse Xenon Pharmaceuticals Inc. (Nasdaq:... 
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Fundamentals and a Bullish Chart Pattern ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Fits the GARP Strategy with Strong Growth and Reasonable Valuation ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Screens as a Compelling Value Investment ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Reports Q4 2025 Earnings Miss Amid Strong Annual Sales Growth ↗
Via Chartmill
Topics Earnings
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup ↗
Via Chartmill
News headline image
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗
This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead ↗
Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition ↗
This UK-based biotech advances clinical-stage therapies for rare diseases, targeting specialty care markets with a diversified pipeline. 
Via The Motley Fool
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Prime Affordable Growth Stock ↗
Via Chartmill
Neurocrine Biosciences Inc. (NASDAQ:NBIX) Presents a Compelling Value Investment Case ↗
Via Chartmill
CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial ↗
Via Stocktwits
News headline image
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients with limited treatment options. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider ↗
BrightSpring Health Services delivers integrated pharmacy and clinical care to Medicare, Medicaid, and insured patients nationwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Neurocrine (NBIX) Q4 2025 Earnings Call Transcript ↗
Neurocrine (NBIX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Offers a Prime Example of Growth at a Reasonable Price ↗
Neurocrine Biosciences exemplifies GARP investing, blending strong earnings growth, solid profitability, and a reasonable stock price within its sector. 
Via Chartmill
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Combines Strong Fundamentals with Bullish Technical Setup ↗
Neurocrine Biosciences (NBIX) combines strong growth, high profitability, and a positive technical breakout setup in the neuroscience sector. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.